[EN] IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES<br/>[FR] COMPOSÉS IMIDAZOPYRIDAZINE UTILES EN TANT QUE MODULATEURS DE RÉPONSES À IL-12, IL-23 ET/OU IFNΑ
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2015089143A1
公开(公告)日:2015-06-18
Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
[EN] PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIMIDINE-2,4-DIAMINE EN TANT QU'INHIBITEURS DE KINASE
申请人:AURIGENE DISCOVERY TECH LTD
公开号:WO2014091265A1
公开(公告)日:2014-06-19
The present application relates to novel Pyrimidine-2,4-diamine derivatives as kinase inhibitors derivatives of formula (I), as protein kinase inhibitors. Formula (I). The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to prodrugs, derivatives, polymorphs, pharmaceutically acceptable salts and compositions comprising the said novel Pyrimidine-2,4-diamine derivatives as kinase inhibitors and their derivatives and their use in the treatment of various disorders.
Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-α responses
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US10273237B2
公开(公告)日:2019-04-30
Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
申请人:Bristol-Myers Squibb Company
公开号:EP3080131A1
公开(公告)日:2016-10-19
METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY
申请人:Whalen Anne
公开号:US20110224128A1
公开(公告)日:2011-09-15
The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient.